25th Annual

SAN DIEGO HEART FAILURE WINTER SYMPOSIUM

New Strategies for Detection, **PREVENTION AND** TREATMENT OF HEART FAILURE

JANUARY 17 & 18, 2025

A Hybrid Event Hilton La Jolla Torrey Pines La Jolla, California

"I've learned so much especially the new studies/ research/practices." A7

"Кеер ир а great job in educating medical professionals and bringing exciting innovations to me with the topics and practice" CR

quality of presenters' SL.

"Symposium

continues to amaze

COURSE DESCRIPTION



This year's 25th Annual San Diego Heart Failure Winter Symposium -New Strategies for Detection, Prevention and Treatment of Heart Failure on January 17 & 18, 2025 will provide a comprehensive overview of strategies for detecting, preventing and treating heart failure. The talks, panel discussions and case presentations will focus on best practices and recent guideline recommendations as interpreted through the eyes of a renowned faculty. Throughout the two days, the faculty will provide expert insight and personal experience as they discuss the full range of management options that are available for patients throughout the spectrum of heart failure, ranging from Stage A (asymptomatic patients with risk factors) all the way to Stage D heart failure (highly symptomatic end-stage patients). New approaches for diagnosing heart failure and identifying specific groups of patients that require special management considerations (such as amyloid, hypertrophic and genetic cardiomyopathies) will be highlighted, rationale for guideline directed medical therapies (GDMTs) will be reviewed and strategies for successful implementation will be presented.

The Symposium combines didactic talks, panel discussions, case presentations and patient perspectives to provide a full and balanced overview of relevant management issues. The four highly focused sessions that comprise this year's Symposium will cover topics related to Populations and Patients at Risk (Session I), Amyloid Heart Disease, Infiltrative Heart Disease, Hypertrophic and Other Forms of Inherited Cardiomyopathy (Session II), Identifying and Treating Heart Failure (Session III), Cardiogenic Shock, Percutaneous Devices to Support Cardiac Function, Emerging Strategies for Preventing Sudden Cardiac Death and Advances in Catheter Based Treatment of Atrial Fibrillation and Valvular Disease (Session IV). During each session, the audience will have an opportunity to comment on the talks and question the faculty on their thoughts about the best approaches for patient management. Our goal, as always, is to provide cutting edge information in a format that will enhance adaption of the knowledge that is gained into clinical practice.

SYMPOSIUM OBJECTIVES

At the conclusion of this program, the participant should be able to:

- 1. Summarize current and emerging treatments available for preventing and treating heart failure and provide information to help in the selection of the most effective choices in individual patients.
- 2. Review strategies for implementing medical and device therapies that will lead to improved outcomes in heart failure patients.
- 3. Define how specific populations including minorities, women and the elderly respond to various approaches to treating risk factors and heart failure.

ACCREDITATION

TARGET AUDIENCE

This course is designed for cardiologists, internists, primary care physicians, nurses, PA's, PharmD's and all other allied healthcare professionals with an interest in heart failure.

NEEDS ASSESSMENT

Over five million Americans (two percent of the U.S.) are living with heart failure (HF). An estimated 670,000 new cases of HF are diagnosed each year and this condition is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years) and is the number one cause of hospitalizations of the elderly in the U.S. HF is common, but unrecognized and often misdiagnosed. Recent data have shown that drugs and devices that have proven beneficial and are recommended in recent practice guidelines, (HFSA 2010 update of practice guidelines Lindelfield J et al J Cardiac Failure 2010:16; 475) are underutilized (Fonarow GC et al. Circulation 2010;122:585).

Recent information also suggests a significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF and a substantial gap in overall performance. In addition, according to a study analyzing the quality of health care in the U.S. on average, patients with heart failure received the recommended quality of care only 64% of the time (heart failure performance measurement set by the ACC/AHA 2010).

Despite important advances in treatment, patients with HF continue to experience unacceptably high rates of morbidity and mortality. This along with the enormous cost of caring for a growing number of HF patients has resulted in increased scrutiny of existing and emerging therapies.

ACCREDITATION

PHYSICIANS

The AAFP has reviewed **25th Annual San Diego Heart Failure Winter Symposium** - **New Strategies for Detection, Prevention and Treatment of Heart Failure** and deemed it acceptable for up to **11.5** Live AAFP Prescribed credits. Term of Approval is from 01/17/2025 to 01/18/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)TM toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

CULTURAL AND LINGUISTIC COMPETENCY

This activity is in compliance with California Assembly Bill 1195 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables health care professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient's primary language. Cultural and linguistic competency was incorporated into the planning of this activity.

FACULTY

UC SAN DIEGO PROGRAM DIRECTOR



Barry H. Greenberg, MD, FACC Distinguished Professor of Medicine Director, Advanced Heart Failure Treatment Program UC San Diego La Jolla, CA

GUEST FACULTY

Uri Elkayam, MD, FACC, FAHA, FHFSA



Professor of Medicine Professor of Obstetrics and Gynecology Director Maternal Cardiology University of Southern California Los Angeles, CA



Gregg Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of Cardiovascular Medicine and Science Director, Ahmanson – UCLA Cardiomyopathy Center Co-Director, UCLA Preventative Cardiology Program Interim Chief, UCLA Division of Cardiology David Geffen School of Medicine Los Angeles, CA



Eldrin Lewis, MD, MPH Simon H. Stertzer, MD, Professor Chief of Division of Cardiovascular Medicine Professor of Cardiovascular Medicine Stanford, CA



Athena Philis-Tsimikas, MD Corporate Vice President, Scripps Whittier Diabetes Institute Scripps Health Director, Community Engagement, Scripps Research Translational Institute San Diego, CA

UC SAN DIEGO PARTICIPATING FACULTY



Eric Adler, MD, FACC Professor of Medicine The Czarina and Humberto S. Lopez Chancellors Endowed Chair in Cardiology Director Strauss Center for Cardiomyopathy & Section Head Heart Failure



Lori Daniels, MD, MAS, FACC, FAHA Medical Director, Cardiovascular Intensive Care Unit Professor of Medicine Division of Cardiovascular Medicine

Laith Alshawabkeh, MD, MSCI, FACC Associate Professor of Clinical Medicine

Director, Adult Congenital Heart Program



Cheryl A.M. Anderson, PhD, MPH, MS Professor and Dean Hood Family Endowed Dean's Chair in Public Health



Kimberly N. Hong, MD, MHSA

Assistant Professor of Medicine Advanced Heart Failure, Cardiac Transplant and Mechanical Circulatory Support

Jonathan C. Hsu, MD, MAS Professor of Medicine Section of Cardiac Electrophysiology Division of Cardiology

FACULTY

UC SAN DIEGO PARTICIPATING FACULTY (continued)



Trina Huynh, PharmD, BCPS Transitions of Care Coordinator Department of Pharmacy



Jia Shen, MD, MPH, FACC Associate Professor of Medicine Director Bankers Hill Cardiovascular Clinics Department of Cardiology



Jade Kozuch, PharmD, BCTXP Pharmacist Specialist, Cardiothoracic Transplant and Mechanical Circulatory Support



Jorge Silva Enciso, MD, FACC Clinical Professor of Medicine Director, Hypertrophic Cardiomyopathy Program Heart Failure, Mechanical Circulatory Support and Transplant Cardiology



David E. Krummen, MD, FACC, FHRS Director of Electrophysiology, VA San Diego Healthcare System Professor of Medicine



Iulia McCain, PA-C Advanced Heart Failure



Pam R. Taub, MD, FACC, FASPC Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center Professor of Medicine UC San Diego Health System Division of Cardiovascular Medicine

Howie Tran, MD, FACC Associate Professor of Medicine Director. Heart Failure Services Director, Cardiogenic Shock and Mechanical Circulatory Support Division of Cardiovascular Medicine



Melissa Mclenon, NP Nurse Practitioner, Surgery





Marcus Anthony Urey, MD Associate Professor of Medicine Department of Medicine



Anya Narezkina, MD Associate Clinical Professor of Medicine Director, Cardio-Oncology Program



Nicholas Wettersten, MD, FACC Assistant Professor of Medicine Department of Cardiology



Demos Papamatheakis, MD Professor of Clinical Medicine Pulmonary Vascular Section Pulmonary, Critical Care, Sleep Medicine and Physiology



Rvan Reeves, MD Associate Professor of Medicine Director, Interventional Cardiology Fellowship Training Program UCSD Sulpizio Cardiovascular Center VA San Diego Healthcare System



Hilary Shapiro, MD, MSc Assistant Clinical Professor of Medicine Advanced Heart Failure and Transplant Cardiology



Michael J. Wilkinson, MD, FACC Assistant Clinical Professor of Medicine Division of Cardiovascular Medicine



Andrew Willeford, PharmD, Health Sciences Assistant Clinical

Skaggs School of Pharmacy and Pharmaceutical Sciences

FRIDAY, JANUARY 17

7:30-8:30am	Registration/Visit Exhibits
8:30-9:30	Product Theatre I - (Non-CME, Breakfast Served)
9:40	Welcome and Introduction to the Symposium Barry Greenberg, MD
SESSION I	Patients and Populations at Risk for Developing Heart Failure Pam Taub, MD (Moderator)
9:50-10:10am	Identifying Patients at Risk for Developing Heart Failure Pam Taub, MD
10:10-10:30	Using SGLT inhibitors to Prevent CV Disease and Heart Failure Jia Shen, MD
10:30-10:50	FEATURED LECTURE I GLP-1 Agonists for Reducing Weight, Preventing CV Disease and Treating Heart Failure Athena Tsimikas, MD
10:50-11:10	Identifying and Treating Patients with Dyslipidemia Michael Wilkinson, MD
11:10-11:30	Use of Non-Steroidal MRAs To Prevent CV Disease, CKD and Heart Failure Nick Wettersten, MD
11:30-11:50	Identifying Patients at Risk for Cardiac Toxicity from Chemotherapy - Update on How to Monitor and Preventive Strategies Anya Narezkina, MD
11:50-12:00	What Do Patients Want to Know About Preventing Cardiovascular Disease Patient Advocate
12:00-12:25pm	Reducing Cardiovascular Risk in Our Patients: Case Presentation and Panel Discussion Pam Taub, MD (Moderator) Drs. Shen, Tsimikas, Wettersten, Narezkina and Andrew Williford PharmD, and Patient Advocate (Panelists)
12:25-12:40	Visit Exhibits
12:40-1:40	Product Theatre II - (Non-CME, Lunch Provided)
1:40-1:55	Visit Exhibits
SESSION II	Amyloidosis, Infiltrative Heart Disease, Hypertrophic Cardiomyopathy and Mongenic Cardiomyopathies Marcus Anthony (Tony) Urey, MD (Moderator)
1:55-2:15	FEATURED LECTURE II Recognizing and Treating Patients with Amyloidosis Marcus Anthony (Tony) Urey, MD
2:15-2:35	Cardiac Myosin Inhibitors and Other New Treatment Options for Patients with Hypertrophic Cardiomyopathy Jorge Silva Enciso, MD
2:35-2:55	Identifying and Treating Sarcoidosis and Other Infiltrative Diseases That Cause Heart Failure Kimberly Hong, MD
2:55-3:10	Refreshment Break/Visit Exhibits
	continued on following page

FRIDAY, JANUARY 17 (continued)

3:10-3:30	Gene Therapy for Monogenic Causes of Heart Failure and Other Cardiovascular Diseases Barry Greenberg, MD
3:30-3:50	Pulmonary Arterial Hypertension (PAH) Demosthenes Papamatheakis, MD
3:50-4:10	FEATURED LECTURE III Heart Failure Management in Adult Congenital Heart Disease Laith Alshawabkeh, MD
4:10-4:30	Peripartum Cardiomyopathy Uri Elkayam, MD
4:30-4:50	Case Presentation and Panel Discussion Marcus Anthony (Tony) Urey (Presentor) Drs. Silva, Hong, Greenberg, Papamatheakis, Alshawabkeh, Elkayam and Jade Kozach PharmD (Discussants)
4:50	Adjourn Day 1

Saturday's schedule begins on following page







SATURDAY, JANUARY 18

7:15-7:30am	Registration/Visit Exhibits
7:30am	Coffee and Master Class on Physical Diagnosis Barry Greenberg, MD
8:00-9:00	Product Theatre III - (Non-CME, Breakfast Served)
9:00-9:15	Visit Exhibits
9:15	Welcome and Introduction to Day 2 of the Symposium Barry Greenberg, MD
SESSION III	Identifying and Treating Heart Failure Barry Greenberg, MD (Moderator)
9:15-9:30	Monitoring Devices To Identify and Treat Congestion Hao (Howie) Tran, MD
9:30-9:45	Treating Patients with HFrEF-The Four Pillars of Therapy Gregg Fonarow, MD
9:45-10:00	Implementing GDMT for Heart Failure-What's the Best Approach? Gregg Fonarow, MD
10:00-10:15	Adjunctive Medical Therapy for Treating Patients with HFrEF Uri Elkayam, MD
10:15-10:35	FEATURED LECTURE IV Treating Patients with HFpEF – How Do the Experts Do It? Eldrin Lewis, MD
10:35-10:50	Coffee Break/Visit Exhibits
10:50-11:05	Using Biomarkers To Identify and Manage Heart Failure Lori Daniels, MD
11:05-11:20	FEATURED LECTURE V How to Talk So Patients with Listen/How to Listen So Patients Will Talk Julia McCain, PA and Trina Huynh, PharmD
11:20-11:35	Identifying Social Determinants That Predispose to Heart Failure and Affect Strategies for Treatment Cheryl Anderson, PhD
11:35-11:45	Living with Heart Failure: A Patient's Perspective Patient Advocate
11:45-12:10	Case Presentation Barry Greenberg, MD (Moderator) Drs. Fonarow, Tran, Elkayam, Daniels, Anderson, Lewis and Julia McCain, PA, Trina Huynh PharmD and Patient Advocate (Panelists)
12:10-12:25pm	Visit Exhibits
12:25-1:25	Product Theatre IV - (Non-CME, Lunch Provided)
1:25-1:40	Visit Exhibits

Saturday's schedule continues on following page

SATURDAY, JANUARY 18 (continued)

SESSION IV	Cardiogenic Shock, Percutaneous Devices to Support Cardiac Function, Strategies for Preventing Sudden Cardiac Death and Catheter Based Treatment of Atrial Fibrillation and Valvular Disease Lori Daniels, MD (Moderator)
1:40-2:00	Identifying and Treating Cardiogenic Shock Lori Daniels, MD
2:00-2:20	Percutaneous Devices for Temporary Support of Cardiac Function Howie Tran, MD
2:20-2:40	Catheter Based Treatments of Valvular Heart Disease Ryan Reeves, MD
2:40-3:00	Left Atrial Occlusion Devices for Preventing Thromboemboli Complications of Atrial Fibrillation Jonathan Hsu, MD
3:00-3:10	Coffee Break/Visit Exhibits
SESSION IV	Emerging Strategies for Detecting and Treating Sudden Cardiac Death and Advanced Heart Failure Hao (Howie) Tran, MD (Moderator)
3:10-3:30	Advances in Preventing Sudden Cardiac Death in Patients with Heart Failure David Krummen, MD
3:30-3:50	Featured Lecture VI. Stage D Heart Failure and Available Treatment Options to Improve Outcomes
	Hilary Shapiro, MD
3:50-4:10	Hilary Shapiro, MD Palliative and Hospice Care for Patients with Advanced Heart Failure Eric Adler, MD
3:50-4:10 4:10-4:20	Palliative and Hospice Care for Patients with Advanced Heart Failure
	Palliative and Hospice Care for Patients with Advanced Heart Failure Eric Adler, MD Treatment Options for Advanced Heart Failure: A Patient's Perspective

FACULTY DISCLOSURE

It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual's control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker's outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

LOCATION



Hilton La Jolla Torrey Pines 10950 North Torrey Pines Road

La Jolla, California, 92037, USA (858) 558-1500

1-800-HILTONS (toll free reservations) www.hilton.com

Hotel Reservation Deadline: December 17, 2024.

You'll find us amid the Torrey Pines Golf Course with views of the Pacific Ocean from our rooms. We're less than five miles from Torrey Pines State Beach and the hiking trails of Torrey Pines State Reserve. Enjoy our outdoor pool and tennis courts, as well as exclusive access to daily golf tee times. We are located 15 miles north of San Diego International Airport in the exclusive area of La Jolla and overlooking the legendary Torrey Pines Golf Course

Reservation Deadline: December 17, 2024. If your reservation is not received prior to cut-off date, reservations will be accepted subject to availability. Please specify that you plan to attend the 25th ANNUAL SAN DIEGO HEART FAILURE WINTER SYMPOSIUM so you can receive our special course rate.

HOTEL RATES

Special room rates are offered: Single/Double: \$179 Plus San Diego occupancy tax of 12.66% and resort charge of \$32. Overnight self-parking is \$23 a night and overnight valet is \$43 *(subject to change)*.

First night's deposit or credit card guarantee must accompany reservation. For Reservations call the hotel directly: 1-800-HILTONS

SYMPOSIUM CANCELLATIONS

If your registration must be cancelled and a refund of your fee is desired, your fee, less \$40 for administrative costs, will be refunded upon receipt of a written request that includes your signature. No refunds will be made after January 1, 2025. Please allow up to 12 weeks for a refund.

FURTHER INFORMATION Complete Conference Management 3320 Third Avenue, Ste C San Diego, CA 92103

Register Online at: SanDiegoHeartFailure.com

Register Online: SanDiegoHeartFailure.com REGISTRATION

25TH SD HEART FAILURE SYMPOSIUM JANUARY 17 & 18, 2025 A Hybrid Event From The

HILTON LA JOLLA TORREY PINES LA JOLLA, CALIFORNIA

First Name	
Last Name	
Title	
Office Address	
City	
StateZip	
Phone	
Email	
Professional Specialty	
Special Needs for Disabled	
Registration Fees: \$225 Early Bird Physician Registration – on or before December \$300 Physician Registration – December 18, 2024 or after and on	
\$149 Early Bird Nurse Registration – on or before December 17, \$199 Nurse Registration – December 18, 2024 or after and on-sit	
\$50 Student Registration <i>*Student/Fellow with letter of verification</i>	
CREDIT CARD PAYMENT - Visa, Mastercard, Discover or Am E	x ONLY
Name of Registrant	
Card Number	
Security CodeExp. Date	
Name on Card	
Billing Address	
Signature	
CHECK OR MONEY ORDER PAYMENT (in US dollars) Make payable to:	
San Diego Heart Failure Symposium	
Send or Fax to: Complete Conference Management	
3320 Third Avenue, Suite C	
San Diego, CA 92103	
Fax: 619-299-6675	